- Home
- IFS vs ZLAB Comparison
IFS vs ZLAB Comparison
Compare IFS & ZLAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IFS
- ZLAB
- Stock Information
- Founded
- IFS 1897
- ZLAB 2013
- Country
- IFS Peru
- ZLAB China
- Employees
- IFS N/A
- ZLAB N/A
- Industry
- IFS Commercial Banks
- ZLAB Biotechnology: Pharmaceutical Preparations
- Sector
- IFS Finance
- ZLAB Health Care
- Exchange
- IFS Nasdaq
- ZLAB Nasdaq
- Market Cap
- IFS 3.9B
- ZLAB 3.6B
- IPO Year
- IFS 2019
- ZLAB 2017
- Fundamental
- Price
- IFS $34.58
- ZLAB $30.14
- Analyst Decision
- IFS Buy
- ZLAB Buy
- Analyst Count
- IFS 1
- ZLAB 4
- Target Price
- IFS $30.00
- ZLAB $47.37
- AVG Volume (30 Days)
- IFS 230.2K
- ZLAB 944.8K
- Earning Date
- IFS 05-08-2025
- ZLAB 05-08-2025
- Dividend Yield
- IFS 2.89%
- ZLAB N/A
- EPS Growth
- IFS 70.43
- ZLAB N/A
- EPS
- IFS 3.84
- ZLAB N/A
- Revenue
- IFS $1,334,218,842.00
- ZLAB $418,326,000.00
- Revenue This Year
- IFS N/A
- ZLAB $44.07
- Revenue Next Year
- IFS $6.86
- ZLAB $49.13
- P/E Ratio
- IFS $8.95
- ZLAB N/A
- Revenue Growth
- IFS 25.66
- ZLAB 43.72
- 52 Week Low
- IFS $21.40
- ZLAB $16.01
- 52 Week High
- IFS $36.90
- ZLAB $39.77
- Technical
- Relative Strength Index (RSI)
- IFS 48.67
- ZLAB 46.27
- Support Level
- IFS $35.40
- ZLAB $30.11
- Resistance Level
- IFS $36.90
- ZLAB $31.34
- Average True Range (ATR)
- IFS 0.84
- ZLAB 1.09
- MACD
- IFS -0.18
- ZLAB 0.07
- Stochastic Oscillator
- IFS 14.71
- ZLAB 43.07
About IFS Intercorp Financial Services Inc.
Intercorp Financial Services Inc is a provider of banking, insurance, wealth management services and payments for retail customers and commercial clients in Peru. The company has four operating segments; the Banking segment includes Mainly loans, credit facilities, deposits, and current accounts, the Insurance segment provides life annuity products with single-premium payment and conventional life insurance products and other retail insurance products, the Wealth Management segment provides brokerage and investment management services. Its geographical segments include Peru and Panama.
About ZLAB Zai Lab Limited
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-1218 (CCR8) Solid Tumors, ZL-1310 (DLL3 ADC) ES-SCLC Other NECs, ZL-6301 (ROR1 ADC) Solid Tumors, ZL 6201 (LRRC15 ADC) Solid Tumors.